ATE334682T1 - Verfahren zur herstellung von den trans-4-n- butylcyclohexanoicsaüre- und undecanoicsaüreestern von (7-alpha,11-beta)- dimethyl-17 beta -hydroxy-4-estren-3-one und deren medizynische anwendung - Google Patents

Verfahren zur herstellung von den trans-4-n- butylcyclohexanoicsaüre- und undecanoicsaüreestern von (7-alpha,11-beta)- dimethyl-17 beta -hydroxy-4-estren-3-one und deren medizynische anwendung

Info

Publication number
ATE334682T1
ATE334682T1 AT01922911T AT01922911T ATE334682T1 AT E334682 T1 ATE334682 T1 AT E334682T1 AT 01922911 T AT01922911 T AT 01922911T AT 01922911 T AT01922911 T AT 01922911T AT E334682 T1 ATE334682 T1 AT E334682T1
Authority
AT
Austria
Prior art keywords
beta
acid
dimethyl
undecanoicsic
butylcyclohexanoicsic
Prior art date
Application number
AT01922911T
Other languages
English (en)
Inventor
Richard P Blye
Hyun K Kim
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE334682T1 publication Critical patent/ATE334682T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0074—Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
AT01922911T 2000-03-31 2001-03-30 Verfahren zur herstellung von den trans-4-n- butylcyclohexanoicsaüre- und undecanoicsaüreestern von (7-alpha,11-beta)- dimethyl-17 beta -hydroxy-4-estren-3-one und deren medizynische anwendung ATE334682T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19353000P 2000-03-31 2000-03-31
US19444000P 2000-04-04 2000-04-04

Publications (1)

Publication Number Publication Date
ATE334682T1 true ATE334682T1 (de) 2006-08-15

Family

ID=26889099

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01922911T ATE334682T1 (de) 2000-03-31 2001-03-30 Verfahren zur herstellung von den trans-4-n- butylcyclohexanoicsaüre- und undecanoicsaüreestern von (7-alpha,11-beta)- dimethyl-17 beta -hydroxy-4-estren-3-one und deren medizynische anwendung

Country Status (8)

Country Link
US (1) US7196074B2 (de)
EP (1) EP1272196B1 (de)
JP (1) JP4845320B2 (de)
AT (1) ATE334682T1 (de)
AU (2) AU2001249661B2 (de)
CA (1) CA2402524C (de)
DE (1) DE60121928T2 (de)
WO (1) WO2001074839A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952319A (en) 1997-11-26 1999-09-14 Research Triangle Institute Androgenic steroid compounds and a method of making and using the same
US20030069215A1 (en) * 2001-03-30 2003-04-10 The Government Of The United States Of America, Methods of making and using 7a,11b-dimethyl-17b-hydroxy-4-estren-3-one 17b-trans-4-n-butylcyclohexane carboxylate and 7a,11b-dimethyl-17b-hydroxyestr-4-en-3-one 17-undecanoate
GB0025221D0 (en) * 2000-10-14 2000-11-29 Astrazeneca Ab New process
ATE426610T1 (de) * 2005-02-04 2009-04-15 Us Gov Health & Human Serv Nandrolon-17ss-carbonate
WO2008039482A2 (en) * 2006-09-26 2008-04-03 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
US9517240B2 (en) 2006-09-26 2016-12-13 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
HUE055562T2 (hu) 2011-11-23 2021-11-29 Therapeuticsmd Inc Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP3145489A1 (de) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Natürliche kombinierte hormonersatzformulierungen und therapien
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
BR112018070199A2 (pt) 2016-04-01 2019-01-29 Therapeuticsmd Inc composição farmacêutica de hormônio esteroide
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
WO2021252761A2 (en) * 2020-06-11 2021-12-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monomeric and oligomeric compound embodiments as contraceptives and therapies and methods of making and using the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3160644A (en) * 1955-08-08 1964-12-08 Upjohn Co 1-dehydro-11-keto-9alpha-fluoro-17alpha-methyl testosterones
US2837517A (en) * 1955-08-08 1958-06-03 Upjohn Co 9, 11beta-epoxy-17-alkyltestosterones
US2806863A (en) * 1956-03-19 1957-09-17 Upjohn Co 9alpha-halo-11beta, 17beta-dihydroxy-17alpha-methylandrostane-3-ones
US3438783A (en) * 1965-08-16 1969-04-15 Monsanto Co Improving egg quality in poultry by orally administering androgens
US3577410A (en) 1968-07-30 1971-05-04 American Home Prod 13beta-alkyl-17-hydroxygona-4,14-dien-3-ones
DE2031849C3 (de) 1970-06-27 1978-11-16 Bosch Gmbh Robert Flüssigkeitsdichte Verbindung eines Deckels aus thermoplastischem Material mit einem Kasten aus thermoplastischem Material
ZA712312B (en) 1970-04-28 1972-01-26 Ochsner Med Found Alton 4,14-estradiene compounds
IL36628A (en) 1970-04-28 1978-08-31 Ochsner Med Found Alton 4, 14-estradiene compounds and processes for their preparation
DE3878198T2 (de) * 1987-12-12 1993-06-24 Akzo Nv 11-arylsteroid-derivate.
FR2747680B1 (fr) * 1996-04-18 1998-07-03 Roussel Uclaf Nouveaux steroides, leur application a titre de medicaments, leur procede de preparation, les intermediaires de ce procede et les compositions pharmaceutiques les renfermant
DE19619045C1 (de) * 1996-05-02 1997-11-13 Jenapharm Gmbh Verwendung von Kombinationspräparaten zur Behandlung hypogonadaler Männer sowie Männern mit Hypophysenerkrankungen
US5952319A (en) * 1997-11-26 1999-09-14 Research Triangle Institute Androgenic steroid compounds and a method of making and using the same
TW548277B (en) * 1999-07-16 2003-08-21 Akzo Nobel Nv Orally active androgens

Also Published As

Publication number Publication date
DE60121928T2 (de) 2007-03-01
AU2001249661B2 (en) 2005-02-17
US7196074B2 (en) 2007-03-27
AU4966101A (en) 2001-10-15
EP1272196A2 (de) 2003-01-08
CA2402524C (en) 2009-11-17
JP2003531119A (ja) 2003-10-21
WO2001074839A2 (en) 2001-10-11
EP1272196B1 (de) 2006-08-02
CA2402524A1 (en) 2001-10-11
JP4845320B2 (ja) 2011-12-28
DE60121928D1 (de) 2006-09-14
US20030130243A1 (en) 2003-07-10
WO2001074839A3 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
ATE334682T1 (de) Verfahren zur herstellung von den trans-4-n- butylcyclohexanoicsaüre- und undecanoicsaüreestern von (7-alpha,11-beta)- dimethyl-17 beta -hydroxy-4-estren-3-one und deren medizynische anwendung
DE50006193D1 (de) Verfahren zur herstellung von otoplastiken und otoplastik
DE60121970D1 (de) Verfahren zur herstellung von pfropfcopolymeren und daraus hergestellte zusammensetzungen
DE60301350D1 (de) Verfahren zur herstellung von 7-substituierten -3-chinolin und 3-chinol-4-on carbonitrile
DE60135596D1 (de) Hohlfasern und Verfahren zur Herstellung von Hohlfasern
DE60206472D1 (de) Verfahren und vorrichtung zur herstellung von mineralwolle
ATE368095T1 (de) Verfahren zur herstellung von mitteldistillaten
DE60142998D1 (de) Verfahren und Apparat zur Herstellung von Quantenpunkt-Strukturen
ATE458823T1 (de) Verfahren zur herstellung von dihydroxyestern und ihren derivaten
DE60326628D1 (de) Dorn und verfahren zur herstellung von stents
DE59905749D1 (de) Verfahren zur herstellung von acrylsäure und acrylsäureestern
ATE291936T1 (de) Kunsthaar und verfahren zur herstellung von haarersatz
DE60232600D1 (de) Verfahren und vorrichtung zur herstellung von percarbonsäure
DE60124143D1 (de) Verfahren zur herstellung von regenerierten collagenfasern und verfahren zu deren fixierung
DE60136748D1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
ATE316959T1 (de) Verfahren zur herstellung von 2- halogenpyridincarbonsäureamiden
DE60214560D1 (de) Verfahren und vorrichtung zur herstellung von faserformkörpern
DE60210184D1 (de) L-cystein herstellendes Bakterium und Verfahren zur Herstellung von L-cystein
DE60126211D1 (de) Zementklinker, zementzusammensetzung, verfahren zur herstellung von zementklinker und verfahren zur behandlung von alkalihaltigen abfällen
DE60210778D1 (de) Verfahren zur herstellung von 4-amino-2,5-bisheterocyclylchinazolinen
ATE292602T1 (de) Verfahren zur herstellung von wasserstoffperoxid
ATE350363T1 (de) Verfahren zur herstellung von alpha- hydroxycarbonsäure amiden
DE50010049D1 (de) Verfahren zur herstellung von mikrostrukturierten bauteilen
ATE332905T1 (de) Verfahren zur herstellung von acylphosphinoxiden
ATE335665T1 (de) System und verfahren zur herstellung von lasteinheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties